Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

被引：0
|
作者：
Amoozgar, Behzad [1 ]
Bangolo, Ayrton, I [2 ]
Uesole, David H. [3 ,4 ]
Siegel, David S. [5 ,6 ]
Biran, Noa [3 ]
Phull, Pooja [3 ]
Donato, Michele L. [7 ]
Parmar, Harsh [3 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[4] Medstar GeorgetownMed Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[6] Ctr Discovery & Innovat, Hackensack, NJ USA
[7] Hackensack Meridian Hlth, John Theurer Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-211671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2408 / 2409
页数：2
相关论文
共 50 条
  • [41] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Lovas, Szilvia
    Varga, Gergely
    Farkas, Peter
    Masszi, Tamas
    Wohner, Nikolett
    Bereczki, Agnes
    Adamkovich, Nora
    Borbenyi, Zita
    Szomor, Arpad
    Alizadeh, Hussain
    Szaleczky, Erika
    Wolf, Krisztina
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Csacsovszki, Otto
    Csukly, Zoltan
    Rajnics, Peter
    Egyed, Miklos
    Nagy, Zsolt
    Rejto, Laszlo
    Illes, Arpad
    Mikala, Gabor
    Varoczy, Laszlo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (05) : 559 - 565
  • [42] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Szilvia Lovas
    Gergely Varga
    Péter Farkas
    Tamás Masszi
    Nikolett Wohner
    Ágnes Bereczki
    Nóra Adamkovich
    Zita Borbényi
    Árpád Szomor
    Hussain Alizadeh
    Erika Szaleczky
    Krisztina Wolf
    Tamás Schneider
    Márk Plander
    Tamás Szendrei
    Ottó Csacsovszki
    Zoltán Csukly
    Péter Rajnics
    Miklós Egyed
    Zsolt Nagy
    László Rejtő
    Árpád Illés
    Gábor Mikala
    László Váróczy
    International Journal of Hematology, 2019, 110 : 559 - 565
  • [43] Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
    Varma, Gaurav
    Fogel, Lindsay
    Gordon, Beth
    Saldarriaga, Mateo Mejia
    Ahn, Jaeil
    Aleman, Adolfo
    Caro, Jessica
    Rosenberg, Maya C.
    Monge, Jorge
    Parmar, Harsh
    Kaminetzky, David
    Moskovits, Tibor
    Siegel, David S.
    Morgan, Gareth J.
    Niesvizky, Ruben
    Davies, Faith E.
    Biran, Noa
    LEUKEMIA & LYMPHOMA, 2025,
  • [44] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [45] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [46] Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
    Sidana, Surbhi
    Peres, Lauren C.
    Hashmi, Hamza
    Hosoya, Hitomi
    Ferreri, Christopher J.
    Atrash, Shebli
    Khouri, Jack
    Voorhees, Peter M.
    Dima, Danai
    Simmons, Gary
    Kalariya, Nilesh
    Hovanky, Vanna
    Bharadwaj, Sushma
    Arai, Sally
    Miklos, David B.
    Wagner, Charlotte B.
    Davis, James
    Sborov, Douglas W.
    Nishihori, Taiga
    Alsina, Melissa
    Locke, Frederick L.
    Gonzalez, Rebecca
    Kocoglu, M. Hakan
    Sannareddy, Aishwarya
    Afrough, Aimaz
    McGuirk, Joseph P.
    Shune, Leyla O.
    Patel, Krina
    Hansen, Doris K.
    BLOOD, 2022, 140 : 10377 - 10379
  • [47] Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
    Kalariya, Nilesh M.
    Hildebrandt, Michelle A. T.
    Hansen, Doris K.
    Sidana, Surbhi
    Khouri, Jack
    Ferreri, Christopher J.
    Doyle, William N.
    Castaneda-Puglianini, Omar
    Freeman, Ciara L.
    Hovanky, Vanna
    Hosoya, Hitomi
    Shune, Leyla O.
    Patel, Krina K.
    BLOOD ADVANCES, 2024, 8 (17) : 4679 - 4688
  • [48] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Ferreri, Christopher
    Kalariya, Nilesh
    Anderson, Larry D., Jr.
    Afrough, Aimaz
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph
    Locke, Frederick L.
    Baz, Rachid
    Patel, Krina K.
    Alsina, Melissa
    HAEMATOLOGICA, 2024, 109 (05) : 1514 - 1524
  • [49] A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
    Furlan, Anna
    Cea, Michele
    Pavan, Laura
    Galli, Monica
    Clissa, Cristina
    Mangiacavalli, Silvia
    Cafro, Anna Maria
    Girlanda, Stefania
    Patriarca, Francesca
    Minotto, Claudia
    Bertoldero, Giovanni
    Barila, Gregorio
    Pascarella, Anna
    Lico, Albana
    Paolini, Rossella
    Rabassi, Nicholas
    Pescosta, Norbert
    Porrazzo, Marika
    De Sabbata, Giovanni
    Pompa, Alessandra
    Bega, Giulia
    Cavallin, Stefania
    Guidotti, Francesca
    Marcatti, Magda
    Rupolo, Maurizio
    Belotti, Angelo
    Gherlinzoni, Filippo
    Zambello, Renato
    CANCER MEDICINE, 2024, 13 (07):
  • [50] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Tan, Carlyn
    Shekarkhand, Tala
    Firestone, Ross
    Jurgens, Eric
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
12345